Opinion/decision on a Paediatric investigation plan (PIP): Nulojix, belatacept, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Renal and urinary disorders, PIP number: P/0351/2024

Opinion/decision on a Paediatric investigation plan (PIP): Nulojix, belatacept, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Renal and urinary disorders, PIP number: P/0351/2024

Human medicines European public assessment report (EPAR): Abrysvo, respiratory syncytial virus vaccine (bivalent, recombinant), Date of authorisation: 23/08/2023, Revision: 12, Status: Authorised

Human medicines European public assessment report (EPAR): Abrysvo, respiratory syncytial virus vaccine (bivalent, recombinant), Date of authorisation: 23/08/2023, Revision: 12, Status: Authorised

Human medicines European public assessment report (EPAR): Menveo, meningococcal group A, C, W-135 and Y conjugate vaccine, Date of authorisation: 15/03/2010, Date of refusal: 17/12/2009, Revision: 39, Status: Authorised

Human medicines European public assessment report (EPAR): Menveo, meningococcal group A, C, W-135 and Y conjugate vaccine, Date of authorisation: 15/03/2010, Date of refusal: 17/12/2009, Revision: 39, Status: Authorised

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.